All In Biotech

NDA 018469 · Alcon

Bss Plus

Calcium Chloride, Dextrose, Glutathione Disulfide, Magnesium Chloride, Potassium Chloride, Sodium Bicarbonate, Sodium Chloride, Sodium Phosphate · Irrigation

Last checked: Nov 20, 2026Latest source record: Apr 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1981

Oct 28, 1981

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9,299

2,122 Phase 3, 968 recruiting

FAERS reports

367

300 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 25, 2024.

INDICATIONS AND USAGE: BSS PLUS solution is indicated for use as an intraocular irrigating solution during intraocular surgical procedures involving perfusion of the eye.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 28, 1981 Original approval · Type 3 - New Dosage Form
1 products under this application
  • BSS PLUS · CALCIUM CHLORIDE 0.154MG/ML; DEXTROSE 0.92MG/ML; GLUTATHIONE DISULFIDE 0.184MG/ML; MAGNESIUM CHLORIDE 0.2MG/ML; POTASSIUM CHLORIDE 0.38MG/ML; SODIUM BICARBONATE 2.1MG/ML; SODIUM CHLORIDE 7.14MG/ML; SODIUM PHOSPHATE 0.42MG/ML · SOLUTION, IRRIGATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.

All 9,299 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • endophthalmitis126
  • toxic anterior segment syndrome71
  • wrong technique in product usage process70
  • corneal oedema50
  • corneal opacity27
  • macular oedema26
  • off label use21
  • product quality issue20
  • eye inflammation19
  • non-infectious endophthalmitis19
  • product preparation error18
  • visual acuity reduced18

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20055
200634
20073
20083
20093
20107
201112
201212
20131
20148
201542
201617
201712
201818
201914
202024
202152
202240
202328
20247
202521
20262

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,116 on PubMed

Sponsor: Alcon

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.